EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

N-/T-Type vs. L-Type Calcium Channel Blocker in Treating Chronic Kidney Disease: A Systematic Review and Meta-Analysis

Mingming Zhao iD, Ziyan Zhang, Zhiyu Pan, Sijia Ma iD, Meiying Chang, Jiao Fan, Shunxuan Xue, Yuejun Wang iD, Hua Qu, Yu Zhang

Pharmaceuticals · 22.02.2023 · 16 (3) · 338

DOI: 10.3390/ph16030338 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 22.02.2023. Verfasst von Mingming Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Capital Health Research and Development of Special, Fundamental Research Funds for the Central public welfare research institutes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renin-angiotensin system (RAS) inhibitors and calcium channel blockers (CCB) are often used together in chronic kidney disease (CKD). The PubMed, EMBASE, and Cochrane Library databases were searched to identify randomized controlled trials (RCTs) in order to explore better subtypes of CCB for the treatment of CKD. This meta-analysis of 12 RCTs with 967 CKD patients who were treated with RAS inhibitors demonstrated that, when compared with L-type CCB, N-/T-type CCB was superior in reducing urine albumin/protein excretion (SMD, −0.41; 95% CI, −0.64 to −0.18; p < 0.001) and aldosterone, without influencing serum creatinine (WMD, −3.64; 95% CI, −11.63 to 4.35; p = 0.37), glomerular filtration rate (SMD, 0.06; 95% CI, −0.13 to 0.25; p = 0.53), and adverse effects (RR, 0.95; 95% CI, 0.35 to 2.58; p = 0.93). In addition, N-/T-type CCB did not decrease the systolic blood pressure (BP) (WMD, 0.17; 95% CI, −1.05 to 1.39; p = 0.79) or diastolic BP (WMD, 0.64; 95% CI, −0.55 to 1.83; p = 0.29) when compared with L-type CCB. In CKD patients treated with RAS inhibitors, N-/T-type CCB is more effective than L-type CCB in reducing urine albumin/protein excretion without increased serum creatinine, decreased glomerular filtration rate, and increased adverse effects. The additional benefit is independent of BP and may be associated with decreased aldosterone (PROSPERO, CRD42020197560).

Schlagwörter

Stichwörter der Autor:innen

L-type calcium channel blockerN-type calcium channel blockerT-type calcium channel blockerchronic kidney diseaseproteinuria

Autor:innen und Institutionen

  • Department of Nephrology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
  • Beijing University of Chinese Medicine, Beijing 100029, China.
  • Department of Geriatrics, Zhejiang Aged Care Hospital, Hangzhou Normal University, Hangzhou 310015, China.
  • Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
  • NMPA Key Laboratory for Clinical Research and Evaluation of Traditional Chinese Medicine, Beijing 100091, China.
  • National Clinical Research Center for Chinese Medicine Cardiology, Beijing 100091, China.

ORCID-Profile: Mingming Zhao, Sijia Ma, Yuejun Wang

Förderung

  • National Natural Science Foundation of China
  • Capital Health Research and Development of Special
  • Fundamental Research Funds for the Central public welfare research institutes
  • the Beijing Municipal of Science and Technology Major Project
  • CACMS Innovation Fund
  • Innovative Funding for PhD Students at China Academy of Chinese Medical Sciences
  • Beijing Municipal of Science and Technology Major Project

Zitieren

APA

Zhao, M., Zhang, Z., Pan, Z., Ma, S., Chang, M., Fan, J., Xue, S., Wang, Y., Qu, H., & Zhang, Y. (2023). N-/T-Type vs. L-Type Calcium Channel Blocker in Treating Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Pharmaceuticals, 16(3), 338. https://doi.org/10.3390/ph16030338

Vancouver

Zhao M, Zhang Z, Pan Z, Ma S, Chang M, Fan J, et al. N-/T-Type vs. L-Type Calcium Channel Blocker in Treating Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Pharmaceuticals. 2023;16(3):338. doi:10.3390/ph16030338

BibTeX
@article{Zhao2023,
  author = {Zhao, Mingming and Zhang, Ziyan and Pan, Zhiyu and Ma, Sijia and Chang, Meiying and Fan, Jiao and Xue, Shunxuan and Wang, Yuejun and Qu, Hua and Zhang, Yu},
  title = {N-/T-Type vs. L-Type Calcium Channel Blocker in Treating Chronic Kidney Disease: A Systematic Review and Meta-Analysis},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {3},
  pages = {338},
  doi = {10.3390/ph16030338}
}
Kostenlos starten →